
## Bradley C Leibovich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7201947/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 512-524.	1.6	6
2	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. European Urology, 2022, 81, 576-585.	1.9	21
3	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e1-166.e8.	1.6	5
4	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. European Urology, 2022, 81, 229-233.	1.9	12
5	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. Human Pathology, 2022, 124, 85-95.	2.0	2
6	Perioperative Outcomes for Radical Nephrectomy and Level III-IV Inferior Vena Cava Tumor Thrombectomy in Patients with Renal Cell Carcinoma. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 3093-3100.	1.3	2
7	Renal neoplasia with papillary architecture involving the pelvicalyceal system. Human Pathology, 2021, 107, 46-57.	2.0	7
8	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 135.e1-135.e8.	1.6	2
9	Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. European Urology, 2021, 79, 225-231.	1.9	25
10	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	1.9	4
11	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Annals of Neurology, 2021, 89, 1001-1010.	5.3	27
12	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. Journal of Urology, 2021, 205, 1303-1309.	0.4	5
13	A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor. Journal of the American Society of Nephrology: JASN, 2021, 32, 2623-2633.	6.1	21
14	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. Mayo Clinic Proceedings, 2021, 96, 1470-1489.	3.0	31
15	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	2.0	19
16	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2021, 5, 129-135.	0.4	0
17	Partial versus radical nephrectomy in clinical T2 renal masses. International Journal of Urology, 2021, 28, 1149-1154.	1.0	14
18	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Human Pathology, 2021, 114, 9-18.	2.0	37

#	Article	IF	CITATIONS
19	Collecting duct carcinoma: A singleâ€institution retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 13.e9-13.e18.	1.6	4
20	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	5.9	4
21	Percutaneous Image-guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. Urology, 2020, 135, 95-100.	1.0	18
22	Concordance of PDâ€1 and PDâ€L1 (B7â€H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Medicine, 2020, 9, 1152-1160.	2.8	17
23	Comparison of prescribing patterns before and after implementation of evidence-based opioid prescribing guidelines for the postoperative urologic surgery patient. American Journal of Surgery, 2020, 220, 499-504.	1.8	13
24	Renal Neuroendocrine Neoplasms: A Single-center Experience. Clinical Genitourinary Cancer, 2020, 18, e343-e349.	1.9	14
25	The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 41.e19-41.e27.	1.6	8
26	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. Human Pathology, 2020, 103, 1-13.	2.0	10
27	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	9.0	109
28	Safety and Efficacy of Retrograde Pyeloperfusion for Ureteral Protection during Renal Tumor Cryoablation. Journal of Vascular and Interventional Radiology, 2020, 31, 1249-1255.	0.5	9
29	Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes?. Kidney Cancer, 2020, 4, 111-115.	0.4	3
30	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. Journal of the American Society of Nephrology: JASN, 2020, 31, 2642-2652.	6.1	30
31	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. BMC Urology, 2020, 20, 173.	1.4	1
32	Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma. Urology, 2020, 140, 98-106.	1.0	10
33	Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 640.e13-640.e22.	1.6	7
34	Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. Journal of Urology, 2020, 203, 275-282.	0.4	44
35	Reply by Authors. Journal of Urology, 2020, 203, 282-282.	0.4	0
36	Impact of a 3D printed model on patients' understanding of renal cryoablation: a prospective pilot study. Abdominal Radiology, 2019, 44, 304-309.	2.1	19

#	Article	IF	CITATIONS
37	Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear ell renal cell carcinoma. BJU International, 2019, 123, 270-276.	2.5	44
38	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	2.4	35
39	Incidence of succinate dehydrogenase and fumarate hydratase–deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Human Pathology, 2019, 91, 114-122.	2.0	57
40	Survival outcomes for patients with surgically induced end-stage renal disease. Canadian Urological Association Journal, 2019, 14, E65-E73.	0.6	0
41	Wide Variation in Opioid Prescribing After Urological Surgery in Tertiary Care Centers. Mayo Clinic Proceedings, 2019, 94, 262-274.	3.0	37
42	Patient-Reported Outcomes After Percutaneous Renal Ablation: Initial Experience. American Journal of Roentgenology, 2019, 212, 672-676.	2.2	5
43	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
44	Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766–72. Partial Nephrectomy: "Geocentrism―of the 21st century in the Church of Urology?. European Urology, 2019, 76, e67-e68.	1.9	0
45	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	5.5	49
46	Partial Versus Radical Nephrectomy for the Clinical T1a Renal Mass. European Urology Focus, 2019, 5, 970-972.	3.1	4
47	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nature Reviews Nephrology, 2019, 15, 423-433.	9.6	68
48	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. BMJ Open, 2019, 9, e025662.	1.9	4
49	The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 932-940.	1.6	5
50	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2019, 2, 141-149.	5.4	73
51	The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	8.4	59
52	Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. European Urology, 2019, 75, 766-772.	1.9	75
53	Frequency and Predictors of Renal Transplantation Among Patients Rendered Surgically Anephric for Sporadic Renal Cancer. Urology, 2019, 126, 134-139.	1.0	1
54	Predictors of Urology Resident Surgical Skills, Clinical Communication Skills, Common Sense and In-Service Scores. Urology Practice, 2019, 6, 52-57.	0.5	6

#	Article	IF	CITATIONS
55	Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. Journal of Urology, 2019, 202, 69-75.	0.4	8
56	Percutaneous resection of metastatic renal cell carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 640.	1.5	2
57	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2018, 115, 119-124.	1.0	19
58	Correlation of Online Physician Reviews and Overall Patient Satisfaction. Mayo Clinic Proceedings, 2018, 93, 404-405.	3.0	6
59	Synchronous nephronâ€sparing approaches for bilateral renal masses: periâ€operative and renal functional outcomes. BJU International, 2018, 122, 243-248.	2.5	12
60	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	1.9	51
61	Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. European Urology, 2018, 73, 772-780.	1.9	131
62	Re: Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis. Journal of Urology, 2018, 199, 1351-1352.	0.4	3
63	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 2018, 199, 1143-1148.	0.4	46
64	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and metaâ€analysis. BJU International, 2018, 121, 684-698.	2.5	79
65	Reply by the Authors. Urology, 2018, 115, 190.	1.0	Ο
66	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2018, 200, 528-534.	0.4	59
67	Inferior vena cava tumour thrombus and renal cell carcinoma. Canadian Journal of Anaesthesia, 2018, 65, 588-589.	1.6	Ο
68	Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis. European Urology, 2018, 73, 254-259.	1.9	45
69	Should Urologists Abandon the Use of Mannitol During Partial Nephrectomy?. European Urology, 2018, 73, 60-61.	1.9	6
70	Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score–based Analysis. European Urology, 2018, 73, 469-475.	1.9	10
71	Systematic Review of the Management of Local Kidney Cancer Relapse. European Urology Oncology, 2018, 1, 512-523.	5.4	30
72	Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. European Urology, 2018, 74, 825-832.	1.9	57

#	Article	IF	CITATIONS
73	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 499.e1-499.e7.	1.6	6
74	Predictors of Scholarly Productivity, Pursuit of Fellowship, and Academic Practice Among Urology Residents Using Medical Student Application Materials. Urology, 2018, 120, 49-55.	1.0	19
75	The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. European Urology, 2018, 74, 489-497.	1.9	93
76	The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. Journal of Urology, 2018, 200, 981-988.	0.4	30
77	Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. Journal of Urology, 2018, 200, 520-527.	0.4	14
78	Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. European Urology, 2017, 71, 665-673.	1.9	80
79	Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. European Urology, 2017, 72, 300-306.	1.9	69
80	Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?. Urology, 2017, 109, 121-126.	1.0	25
81	Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy. Journal of Urology, 2017, 198, 795-802.	0.4	8
82	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. European Urology, 2017, 71, 979-985.	1.9	52
83	The role of imaging, deliberate practice, structure, and improvisation in approaching surgical perfection. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1329-1336.	0.8	42
84	Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. BJU International, 2017, 120, 544-549.	2.5	19
85	TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Modern Pathology, 2017, 30, 998-1012.	5.5	70
86	Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort. BJU International, 2017, 119, 905-912.	2.5	14
87	Subjective and objective heterogeneity scores for differentiating small renal masses using contrast-enhanced CT. Abdominal Radiology, 2017, 42, 1485-1492.	2.1	34
88	Percutaneous Cryoablation of Renal Cell Carcinoma with Sinus Vein Involvement Based on Preprocedural Imaging. Journal of Vascular and Interventional Radiology, 2017, 28, 1651-1657.	0.5	3
89	Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology, 2017, 109, 145-152.	1.0	4
90	Predictors of a Successful Urology Resident Using Medical Student Application Materials. Urology, 2017, 108, 22-28.	1.0	33

#	Article	IF	CITATIONS
91	Coffee consumption and risk of renal cell carcinoma. Cancer Causes and Control, 2017, 28, 857-866.	1.8	16
92	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urology, 2017, 17, 19.	1.4	26
93	Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU International, 2017, 119, 116-127.	2.5	33
94	Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. Journal of Urology, 2017, 197, 574-579.	0.4	41
95	Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. European Urology, 2017, 71, 560-567.	1.9	58
96	Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 36.e1-36.e6.	1.6	9
97	Urinary collecting system invasion is associated with poor survival in patients with clearâ€cell renal cell carcinoma. BJU International, 2017, 119, 585-590.	2.5	15
98	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403–6. European Urology, 2017, 71, e47-e48.	1.9	3
99	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology, 2017, 99, 155-161.	1.0	17
100	Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU International, 2016, 118, 742-749.	2.5	32
101	Three-dimensional Printing for Renal Cancer and Surgical Planning. European Urology Focus, 2016, 2, 574-576.	3.1	12
102	Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406.	1.9	80
103	Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. Urology, 2016, 96, 106-113.	1.0	9
104	Surgical Management and Oncologic Outcomes of Recurrent Venous Tumor Thrombus after Prior Nephrectomy for Renal Cell Carcinoma. European Urology Focus, 2016, 2, 625-630.	3.1	6
105	Differentiation of Benign From Metastatic Adrenal Masses in Patients With Renal Cell Carcinoma on Contrast-Enhanced CT. American Journal of Roentgenology, 2016, 207, 1031-1038.	2.2	23
106	Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. World Journal of Urology, 2016, 34, 1465-1472.	2.2	19
107	Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors. World Journal of Urology, 2016, 34, 1693-1699.	2.2	17
108	Assessing the Evidence for the Surgical Management of Renal Cell Carcinoma with Venous Tumor Thrombus: Room to Grow. European Urology, 2016, 70, 281-282.	1.9	6

#	Article	IF	CITATIONS
109	Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series. Urology Practice, 2016, 3, 124-133.	0.5	2
110	Observations on transatlantic renal cell cancer surgery outcomes. BJU International, 2016, 117, 212-214.	2.5	1
111	Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. Journal of Urology, 2016, 195, 270-276.	0.4	104
112	Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. European Urology, 2016, 69, 84-91.	1.9	47
113	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e15-505.e20.	1.6	7
114	Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus. BJU International, 2015, 116, 388-396.	2.5	66
115	The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clinical Genitourinary Cancer, 2015, 13, 476-484.	1.9	19
116	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	7.0	33
117	Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 216-229.	2.0	106
118	Small (< 4 cm) Renal Masses: Differentiation of Angiomyolipoma Without Visible Fat From Renal Cell Carcinoma Using Unenhanced and Contrast-Enhanced CT. American Journal of Roentgenology, 2015, 205, 1194-1202.	2.2	59
119	Combination of a fillet flap, free tissue transfer, and autologous tissue grafts in pelvic reconstruction following retroperitoneal sarcoma: A case report. Microsurgery, 2015, 35, 320-323.	1.3	1
120	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.4	32
121	The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization. Urology, 2015, 85, 442-451.	1.0	35
122	The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e11-388.e18.	1.6	16
123	Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. European Urology, 2015, 68, 5-7.	1.9	25
124	The High-Dose Aldesleukin "Select―Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	7.0	133
125	Small (< 4 cm) Renal Mass: Differentiation of Oncocytoma From Renal Cell Carcinoma on Biphasic Contrast-Enhanced CT. American Journal of Roentgenology, 2015, 205, 999-1007.	2.2	66
126	The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 67.e15-67.e23.	1.6	23

#	Article	IF	CITATIONS
127	Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy Journal of Clinical Oncology, 2015, 33, 420-420.	1.6	Ο
128	The impact of rhabdoid differentiation on prognosis in patients with grade 4 renal cell carcinoma Journal of Clinical Oncology, 2015, 33, 494-494.	1.6	0
129	Association and prognostic impact of peripheral blood counts with tumor programmed death ligand one expression Journal of Clinical Oncology, 2015, 33, 447-447.	1.6	Ο
130	Prognostic impact of peripheral blood counts in patients with non-metastatic clear cell renal cell carcinoma Journal of Clinical Oncology, 2015, 33, e15590-e15590.	1.6	0
131	Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1277-1284.	1.6	46
132	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma—The Mayo Clinic experience. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 24.e1-24.e6.	1.6	12
133	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. European Urology, 2014, 66, 584-592.	1.9	100
134	Diabetes Mellitus is Independently Associated with an Increased Risk of Mortality in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1620-1627.	0.4	33
135	Mayo Adhesive Probability Score: An Accurate Image-based Scoring System to Predict Adherent Perinephric Fat in Partial Nephrectomy. European Urology, 2014, 66, 1165-1171.	1.9	190
136	Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. European Urology, 2014, 66, 929-935.	1.9	29
137	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. Journal of Urology, 2014, 192, 1050-1056.	0.4	76
138	Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial) Journal of Clinical Oncology, 2014, 32, TPS4606-TPS4606.	1.6	4
139	The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Indian Journal of Urology, 2014, 30, 38.	0.6	5
140	AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy?. Journal of Clinical Oncology, 2014, 32, 402-402.	1.6	8
141	Perioperative outcomes following surgical resection of renal cell carcinoma with upper level IVC thrombus: A contemporary multicenter experience Journal of Clinical Oncology, 2014, 32, 498-498.	1.6	Ο
142	Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy Journal of Clinical Oncology, 2014, 32, 503-503.	1.6	1
143	Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy Journal of Clinical Oncology, 2014, 32, 516-516.	1.6	1
144	Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer, 2011, 117, 2873-2882.	4.1	344

#	Article	IF	CITATIONS
145	Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma. Journal of Urology, 2010, 183, 1309-1316.	0.4	339
146	Surgical Management, Complications, and Outcome of Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy Facilitated by Vascular Bypass. Urology, 2008, 72, 148-152.	1.0	63
147	Surgical Management of Renal Cell Carcinoma. Seminars in Oncology, 2006, 33, 552-562.	2.2	17
148	A SCORING ALGORITHM TO PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A STRATIFICATION TOOL FOR PROSPECTIVE CLINICAL TRIALS. Journal of Urology, 2005, 174, 1759-1763.	0.4	201
149	The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International, 2004, 94, 33-41.	2.5	517
150	PROSTATE CANCER DIAGNOSIS USING A SATURATION NEEDLE BIOPSY TECHNIQUE AFTER PREVIOUS NEGATIVE SEXTANT BIOPSIES. Journal of Urology, 2001, 166, 86-92.	0.4	366
151	Paraganglioma of the urinary bladder. , 2000, 88, 844-852.		105
152	Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. , 2000, 88, 1679-1686.		56
153	Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer, 2000, 88, 2326-2332.	4.1	135
154	Extranodal Extension in Lymph Node–Positive Prostate Cancer. Modern Pathology, 2000, 13, 113-118.	5.5	56
155	Grading and Staging of Bladder Carcinoma in Transurethral Resection Specimens. American Journal of Clinical Pathology, 2000, 113, 275-279.	0.7	124
156	p53 Alteration in regional lymph node metastases from prostate carcinoma. , 1999, 85, 2455-2459.		38
157	Survival of patients with carcinoma in situ of the urinary bladder. Cancer, 1999, 85, 2469-2474.	4.1	143
158	Tumor size predicts the survival of patients with pathologic stage t2 bladder carcinoma. Cancer, 1999, 85, 2638-2647.	4.1	84
159	Hemangioma of the urinary bladder. , 1999, 86, 498-504.		71
160	Neurofibroma of the urinary bladder. Cancer, 1999, 86, 505-513.	4.1	72
161	Unplanned Conversion from Partial to Radical Nephrectomy – An Analysis of Incidence, Etiology, and Risk Factors. Journal of Urology, 0, , .	0.4	1